Investigating treatments to help infants with HIV-1 achieve remission without lifelong therapy
Official title: Impact of Neonatal ART and Broadly Neutralizing Antibodies on HIV-1 Reservoirs in Infants: Towards ART-free Remission
Funded at Johns Hopkins University · NIH-11142403 · Data updated 2026-11-12
This study is looking at ways to help babies with HIV-1 possibly stop needing lifelong medication by testing early treatments and special antibodies to see if they can reduce the hidden virus in their bodies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 22, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $804,830 |
| NIH project number | 5R01AI186792-02 |
| Project ID | NIH-11142403 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants diagnosed with HIV-1, particularly those who are newly infected and starting treatment.
✕Less likely to help
Patients who are older than infancy or those who have already undergone extensive ART may not benefit from this research.
What this research studies
This research focuses on infants infected with HIV-1, aiming to explore new treatment strategies that could allow them to achieve remission without the need for lifelong antiretroviral therapy (ART). The study will investigate the effects of very early ART and the use of broadly neutralizing antibodies (bNAbs) on the size of the HIV-1 reservoir in these infants. By analyzing the composition of proviral pools and their behavior during treatment interruptions, the research seeks to understand how to effectively reduce the virus's hidden reservoirs. This could lead to significant advancements in the treatment of HIV-1 in newborns and infants.
Why it matters
Potential benefit: If successful, this research could enable infants with HIV-1 to achieve remission without the need for continuous ART, improving their quality of life and reducing long-term health complications.
How similar studies have gone: Previous research has shown promise in using early ART and antibody therapies for HIV-1, but this specific approach is still being explored and is considered novel.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Persaud, Deborah — Johns Hopkins University
- Study coordinator: Persaud, Deborah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.